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In peptide sequencing experiments involving a single step tandem mass acquisition, leucine
and isoleucine are indistinguishable because both are characterized by a 113 Da mass
difference from the other peptide fragments in the MS2 spectrum. In this work, we propose a
new method to distinguish between these two amino acids in consecutive MSn experiments,
exploiting a gas-phase fragmentation of isoleucine that leads to a diagnostic 69 Da ion. We
used this method to assess the Leu/Ile residues of several synthetic peptides. The procedure
was then tested on a tryptic digest of myoglobin, assigning the correct amino acid in the
majority of the peptides. This work was performed with an old and low-resolution instrument,
thus demonstrating that our method is suitable for a wide number of ion trap mass
spectrometers, not necessarily expensive or up-to-date. (J Am Soc Mass Spectrom 2007, 18,
57–63) © 2007 American Society for Mass SpectrometryProteome investigation is one of the most impor-tant topics in biomedical research. Over the lastdecade, liquid chromatography, coupled with
electrospray mass spectrometry, has become one of the
most powerful techniques for proteomic analysis. Pro-
tein sequencing by mass spectrometry is routinely
achieved worldwide by collision induced fragmenta-
tion of tryptic peptides. The currently accepted nomen-
clature of the fragments was proposed by Roepstoff and
Fohlman [1] and subsequently modified by Johnson [2,
3] and Bieman [4]. Low collision energies (a few eV)
generate fragment ions carrying charges mainly over
the peptidic backbone, so that a, b, and y ions are
usually predominant in the MS/MS spectrum; b ions
carry the charge on the amino-terminal fragment; y
ions, on the contrary, retain the charge on the carboxy-
terminal fragment. According to Bieman, b and y ions
are numbered from each terminus of the backbone,
respectively. At this level of analysis, leucine and iso-
leucine are virtually indistinguishable. Higher collision
energies (keV level) can generate additional d and w
fragments that enable Leu and Ile to be differentiated
[5]. Unfortunately, the overwhelming majority of in-
struments used for routine proteomic analysis, such as
triple quadrupoles and ion traps, work at low fragmen-
tation energies and, for this reason, the information
about Leu and Ile is usually lost. The Leu/Ile issue has
been extensively investigated over the years: by FAB
ionization [6], by electron impact [7], by formation of
copper complexes [8], or by chemical derivatization [9].
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doi:10.1016/j.jasms.2006.08.011In this work, we propose a new method to achieve this
discrimination with a nearly obsolete, economic, and
low-resolution ion trap instrument by a series of tan-
dem mass steps, and using a relatively low sample
concentration (500 fmol/l). The idea for this work
originated from a practical problem due to a mislabel-
ing incident. Two synthetic HLA nonameric peptides
(A1: VMAPRTLIL and CW3: VMAPRTLLL), identical
for molecular mass and sequence and differing from
each other only for a leucine instead of an isoleucine
residue at position 8, were accidentally exchanged
before cell culture trials. A rapid assessment of the
peptide sequence was therefore requested, to avoid an
expensive new synthesis of both molecules. We first
performed an accurate study of the electrospray-ion
trap fragmentation pattern of leucine and isoleucine as
free amino acids with the purpose to find a fragment
ion diagnostic for our aim. We found that the proton-
ated molecular ion (132 Da) of Ile, unlike Leu, generates,
by loss of ammonia, a high amount of 69 Da ions from
its immonium fragment (86 Da). We then used this
diagnostic ion to unambiguously assign the correct
structure of A1 and CW3. This approach was then
extended to tryptic peptides to deduce a general rule for
specific Xle assessment. To this aim, we synthesized a
family of 10 tryptic-like isomeric hexapeptides, consist-
ing of a series of permutations of the same amino-acidic
sequence, differing for the position of Leu and Ile in the
primary structure. The correct Xle residue was charac-
terized for every position but the last one. As a final
confirmation of the validity of our method, we tested it
on a myoglobin tryptic digest, obtaining satisfactory
results, though with a few limitations, mostly due to
instrumental restraints.The ability to discriminate between Leu and Ile is
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by different mRNA triplets. In a molecular cloning
experiment, the correct mRNA has to be isolated to
obtain the corresponding cDNA to be used, for exam-
ple, to produce the recombinant species of the protein of
interest [10]. For this purpose, the primers to be synthe-
sized for polymerase chain reaction experiments should
be reduced to a minimum. The primers are planned on
the basis of the primary structure of the peptides of the
unknown protein. These sequences are usually deter-
mined by mass spectrometry and de novo sequencing,
but every Xle uncertainty in the peptide adds a 2n
multiplicity for each primer, n being the number of Xle
in the structure. For this reason, a correct Xle assign-
ment decreases the primers multiplicity, allowing sig-
nificant time and costs gain.
Materials and Methods
Mass Spectrometry
All experiments were carried out on an Agilent 1100
MSD (Palo Alto, CA) ion trap mass spectrometer,
equipped with an electrospray ion source. Samples
were dissolved in a formic acid 0.1%/ACN 50/50
solution at a final concentration of 500 fmol/l and
analyzed by direct infusion analysis at 5 l/min flow
rate. Mass spectra were acquired in positive ion mode.
Instrument parameters were set as follows:
• Dry gas (N2): 6 L/min.
• Nebulizer (N2): 10 L/min.
• Dry temperature: 300 °C
• HV capillary: 3500 V
• Octopole: 3.5 V
• Skimmer 1: 25 V (unless otherwise specified).
• Trap drive: 50
In the MSn experiments, collision energies were auto-
matically set by the acquisition software according to
the precursor ion mass to charge ratio.
Peptide Synthesis
Peptides were manually synthesized using the standard
9-fluorenylmethoxycarbonyl (Fmoc) solid-phase strat-
egy, with minor modifications [11].
Tryptic Digestion
Horse myoglobin was dissolved in 1 mM HCl, dripped
in cold acetone and centrifuged at 14,000 rpm for 10
min. The denatured protein was then separated from
the supernatant and resuspended in 50 mM ammonium
bicarbonate at pH 8.5. Peptide sequencing grade trypsin
(Sigma Aldrich, Milano, Italy) at a final weight ratio of
1 to 100 with respect to the protein was then added to
the solution. The sample was incubated at 37 °C over-
night, then diluted in 50/50 water/ACN  0.1% formic
acid at a final concentration of 500 fmol/l.Results
Fragmentation Spectra of Leu and Ile Immonium
Ions
Both Leu and Ile protonated molecular ions (132 Da)
easily generate the corresponding immonium ion (86 Da)
by loss of formic acid. When the immonium is further
fragmented, the MS3 spectrum in Figure 1 is recorded.
Besides the 30 Da and 44 Da ions, common to both amino
acids, Ile, unlike Leu, generates a 69 Da ion that is
diagnostic for our aim. Leucine and isoleucine tandem
mass spectra were obviously acquired at the same colli-
sion energies. This result was previously reported by
Hulst and Kientz in 1996 [12], who observed this behavior
of Ile when subjected to collision with inert gas, and used
the abundance of this diagnostic ion to confirm the rela-
tive Leu/Ile ratio in two large peptides. The chemical
nature of the 69 Da ion of Ile and the gas-phase reaction
mechanism that produces it are currently under investi-
gation, by means of quantum chemistry.
Analysis of CW3 and A1 Peptides
From the MS2 spectrum of the doubly charged form of
the HLA peptides (507.2 Da), the y2 ion (3HN-XL-
COOH, 245 Da) was selected and, when subjected to
MS3 fragmentation, generated the 86 Da immonium ion.
The MS4 spectrum of this last ion answered the issue of
Xle assessment: only one peptide produced the 69 Da
ion and was unambiguously labeled as CW3. More
interestingly, another way to find this information from
the MS2 spectrum proceeded from the doubly charged
b8 ion (3HN-VMAPRTLX-CO
). In the MS3 spectrum
of this fragment, two signals at 227 Da and 199 Da were
analyzed: they matched, respectively, a b8y2 internal
fragment (2HN-LX-CO
) and its decarbonylated form
(2HN-LX
). Both ions generated the 86 Da immonium
in MS4, which allowed the identification of CW3 by the
69 Da ion produced in MS5. This last way required an
additional MS/MS step. A summarizing diagram of
this analysis is reported in Figure 2a and b. The ob-
tained result was then confirmed by the same biological
trials in which HLA-E was recognized by the  T cell
receptors in presence of CW3 only, as expected for a
peptide carrying an Ile residue in position 8 [13].
Xle Residue Characterization
Ten isomeric hexapeptides were specifically synthe-
sized to achieve a complete characterization of Xle
independently of its position in the peptide. The Xle
residue was placed at different positions in the back-
bone (see Figure 3), except for the last one, which was
reserved to K, to simulate the result of a tryptic diges-
tion. The doubly charged form of each peptide (300 Da)
was fragmented. In a deeper analysis of the MS2 spec-
trum, often both y and b series fragments carried the
analysis to a final characterization of Xle. For position 1,
um io
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69 Da was clearly visible in the MS2 spectrum of the Ile
peptide only. Besides that, the b series led, through its
decarbonylated a form, to the 86 Da immonium ion
which, in the subsequent MSn step, originated the 69 Da
diagnostic ion for the Ile peptide only. The b series was
thus used for positions 1 and 2. Getting deeper inside
the peptide (positions 3 and 4), another way to generate
a useful fragment ion had to be found. The y series
proved to be the best choice: for Xle in position 3, the y4
fragment ion (3HN-XAVK-COOH, 430 Da) generated
the internal b4y4 ion (2HNXA-CO
, 185 Da) that,
through the immonium form of Xle, unambiguously
allowed the Xle characterization. We used the same
approach for position 4: in this case, the y3 ion (3HN-
XVK-COOH, 359 Da) produced the internal b5y3 frag-
ment (2HN-XV-CO
, 213 Da) and the y4 ion (3HN-
AXVK-COOH, 430 Da) produced the corresponding
b4y4 (2HN-AX-CO
, 185 Da). Both fragmentation path-
ways led us to the characterization of Xle.
The Problem of Position N-1
With Xle in the second-last position immediately before K,
ourmethod did not produce reliable results. The fragmen-
tation spectrum of the y2 ion (3HN-XK-COOH, 260 Da)
generated a very small amount of the immonium of Xle
and a much higher amount of 84 Da ion (Figure 4). The
latter comes from the immonium of K by loss of ammonia.
The combination of weakness of 86 Da signal and the
presence of a very close (by mass) 84 Da ion did not allow
us to obtain a good MS4 spectrum, since in MS3 our
Figure 1. MS3 spectrum of immoniinstrument does not have an adequate effective resolutionfor isolation of 84 and 86 ions. For this position, we
changed our approach: the skimmer 1 voltage was in-
creased from 25 to 60 V, producing a considerable amount
of 86 Da ion. This fragmentation is not controlled since it
occurs outside the ion trap and it is due to collision of the
protonated sample ions with the nebulizing nitrogen gas
that is pumped out by the vacuum system. The resulting
fragments are then moved to the trap and there analyzed
and further fragmented. The MS2 spectrum of this 86 Da
produced the 69 Da ion for the Ile peptide only. This result
suggests that regular ion trap fragmentation promotes the
immonium form of K, while high voltage-induced unspe-
cific decay of the protonated peptide assists the formation
of immonium form of the adjacent Xle.
Analysis of Myoglobin Tryptic Peptides
The proposed method required to be tested on a real
tryptic sample. For this purpose we used a 500 fmol/l
solution of horse myoglobin tryptic digest, recording
the MSn spectra of the doubly charged form of several
peptides, ranging from 400 to 1800 Da. The obtained
results are summarized and briefly discussed in Table 1.
Discussion
How to Get the Xle Information from a MS2
Spectrum
Once the complete peptide sequence has been obtained,
there is usually more than one way to achieve the Xle
characterization, since both b and y series can often lead to
ns of isoleucine (a) and leucine (b).the 86 Da immonium ion (see Figure 5). As shown, with
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desired information. If these ions are weak, choosing the
strongest adjacent bn1 and yn1 signal is sometimes a
better choice, because it might generate the desired bn and
yn ions with an additional MS/MS step. If the instrument
electronics are fast enough, the immonium ion produced
in MS5 (instead of MS4 will generate the diagnostic ions
alike. As a general rule, strongest signals and lower
masses are to be preferred because they usually produce a
better MSn spectrum, with a higher abundance of the
Figure 2. (a) Tandem mass analysis of peptid
series lead to the final Ile assessment (presence o
both y (italic) and b (underlined) fragment serie
ion).fragment carrying Xle as daughter b ion. In a application-oriented approach, a few guidelines for Xle assessment
can be outlined: if Xle is in the first part of the peptide,
following the b series (and its decarbonylated a subseries)
seems to be the best choice because it often produces the
86 Da immonium ion already in MS3, allowing fragmen-
tation time saving. If Xle is in the last part of a nontryptic
peptide, therefore not ending by K or R, then the same
result can be obtained from the y series. The inner posi-
tions of the peptide are the most difficult to characterize.
In this case y ions are usually more useful than b ions
3: both y (italic) and b (underlined) fragment
a ion). (b) Tandem mass analysis of peptide A1:
d to the final Leu assessment (absence of 69 Dae CW
f 69 D
s leabecause they often produce a Xle-X daughter by internal
from the C-terminus.
to the N-1 position issue resides perhaps in the diffe
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An example of this tandem mass behavior is represented
by the y4 ion of myoglobin peptide NDIAAK (see Figure
6). Yague et al. [14] reported several examples of anoma-
lous peptide fragmentation patterns due to rearrangement
of the b series ions. These signals correspond to neutral
losses of internal amino acids. In such a case, the effective
sequence of the selected b ion changes, affecting the final
assessment of Xle, and using the y series becomes a
mandatory choice. However, in our experiments no direct
evidence of this phenomenon was observed.
As previously described in the Results section, the
second to last position of a tryptic peptide is until now not
appraisable. The difference in the relative abundance of 84
and 86 Da ions in the MS3 spectrum of the y5 fragment of
peptides AVAVXK (Figure 4) might suggest that Ile has a
little advantage respect to Leu in the formation of its own
immonium ion compared with the immonium form of K.
Anyway, if the researcher is confident that just one Xle is
present in the peptide sequence, then the skimmer-in-
duced fragmentation always represent a useful way to
produce the 86 Da immonium ion. If more than one Xle is
present but the 86 Da ion does not generate the 69 Da ion,
then every Xle in the peptide is most likely a Leu.
Conclusions
It is difficult to discriminate between the intrinsic analyt-
ical limitations of this approach and the instrumental
limitations of our ion trap, whose design dates back to
more than ten years ago. In several cases, we were able to
VIK (a) and peptide AVAVLK (b). The answerFigure 3. Synthetic hexapeptides for position-specific Xle assess-
ment. Fragment b ion series begins from the N-terminus, y seriesFigure 4. MS3 spectra of the y5 ion of peptide AVA
rent relative intensity of 84 and 86 Da ions.
62 ARMIROTTI ET AL. J Am Soc Mass Spectrom 2007, 18, 57–63identify the dipeptide fragment carrying the Xle informa-
tion, but its insufficient signal and the low capacity of the
trap prevented us from reaching a further fragmentation
spectrum. In our experience, we were not able to go
reproducibly over a MS5 spectrum, and frequently this
was not enough because sometimes the yn signal was not
clearly visible in the MS2 spectrum and it had to be
Table 1. Myoglobin tryptic peptide analysis.
Myoglobin Peptides
Underlined  correctly assigned
In brackets  ambiguous or partial result
LFTGHPETLEK
MW  1270.6
Leu1 fr
ALELFR
MW  747.4
Leu2 fr
VEADIAGHGQEVLIR
MW  1605.8
Ile5 fro
NDIAAK
MW  630.3
Ile3 fro
IP(I)K
MW  469.3
Ile1 fro
Interna
Y(L)EF(I)SDA(II)HV(L)HSK
MW  1884.0
Analys
GHHEAE(L)KP(L)AQSHATK
MW  1852.9
Analys
HGTVV(L)TALGGI(L)K
MW  1377.8
Leu9 fr
Leu13
Leu6: a
limit
ELGFQG
MW  649.3
Leu2 fr
Figure 5. Summarizing diagram of the tandem
of Xle.obtained by fragmentation of a yn1 or even a yn2 ion.
Every MSn step dramatically reduces the ions abundance
and increases acquisition times. The slow electronics of
our instrument therefore represents themain instrumental
limitations. We are however confident that better per-
forming ion trapsmight by far increase the effectiveness of
our method. In a future HPLS-MS implementation of our
Comments
2; Leu9 from y3
2 and b2; Leu4 from y3
; Leu13 from y3
; Ile3 ambiguous (see text: position N-1 issue)
3 useless probably due to proline see reference [15, 16]
ded at the immonium ion (see text: instrumental limitations)
ded at the immonium ion (see text: instrumental limitations)
6; Ile12 from y3
iguous (see text: position N-1 issue)
sis stopped at the immonium ion (see text: instrumental
s)
2 (singly charged parent ion)
s method used to obtain the immonium ionom a
om a
m b5
m y4
m a1
l b3y
is en
is en
om y
amb
naly
ation
om bmas
own
63J Am Soc Mass Spectrom 2007, 18, 57–63 LEU AND ILE BY LOW ENERGY ESI TRAP MSnmethod, information dependent acquisition software, cou-
pled with up-to-date instruments, might perhaps record
the complete MS2 spectrum, identify the critical yn and bn
signals and proceed to their MS3 analysis. A complete
database of every possible Xle-involving dipeptide b ion
could eventually lead the acquisition through theMS4 and
MS5 steps. As for the natural intrinsic limitations, if the Xle
resides in the central part of the structure, we would not
recommend this approach for peptides larger than 1600 to
1800 Da, because the MS2 fragmentation of these mole-
cules gives rise to large bn and yn ions that hardly generate
the desired Xle dipeptides in the subsequent MSn steps. If,
on the contrary, Xle is at the beginning of the backbone,
the b series can be very often helpful, even for large
peptides. Smaller peptides (500–1000 Da) are easier to
analyze and the correct Xle assignment is possible in a
large number of cases.
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